“The #1 Tech Opportunity of the Decade”

On February 8th, Luke Lango is making his biggest call of 2023. He’s recommending technology (that you’ve likely never heard of) that could help 122 million people… And mint up to $3 trillion in wealth.

Wed, February 8 at 8:00PM ET

CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests

  • Shares of molecular testing specialist Co-Diagnostics (NASDAQ:CODX) are up significantly during early afternoon trading.
  • News about the issuing company shipping monkeypox virus testing reagents boosted CODX stock.
  • This comes after the Covid-19 pandemic lifted CODX stock over the past two years.
CODX stock - CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests

Source: Shutterstock

Specializing in molecular diagnostic polymerase chain reaction (PCR) tests, Co-Diagnostics (NASDAQ:CODX) represents an extremely relevant business in the new normal. Early this morning, the company announced that it shipped testing reagents for the monkeypox virus to one of its international distributors. In response, CODX stock popped around 5% in early afternoon trading.

According to the press release, Co-Diagnostics expedited the development and manufacturing of these reagents due to demand. This comes as the monkeypox virus has been identified in various countries across the globe, including the U.S.

The press release further explained, “According to the World Health Organization (WHO), monkeypox is a virus originally transmitted to humans from animals, and then transmitted from one person to another by close contact with lesions, body fluids, respiratory droplets and contaminated materials such as bedding. As of July 7, 2022, over 6,000 cases of monkeypox have been reported to WHO from 59 countries.”

As the outbreak continues, the fact that tests are on their way, along with vaccines and treatments, is very welcome news.

Another Catalyst for CODX Stock

As you may recall, CODX stock traded hands for a little over $1 just prior to the coronavirus pandemic. Once reports indicated that the SARS-CoV-2 virus breached U.S. borders, Co-Diagnostics shares skyrocketed. At its peak, the market priced the security well into double-digit territory. Then, it suffered a catastrophic decline in the late summer of 2020. Although CODX temporarily bounced higher, it never truly recovered from the devastation.

As of this writing, CODX stock is trending around the $6.28 level. That is well below its peak market value but substantially higher from the beginning of 2020. Interestingly, over the trailing month, CODX is up approximately 25% — with underlying circumstances boding well for Co-Diagnostics.

On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.

Article printed from InvestorPlace Media, https://investorplace.com/2022/07/codx-stock-pops-co-diagnostics-ships-out-monkeypox-tests/.

©2023 InvestorPlace Media, LLC